Kazia Therapeutics Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint
/PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specializing in oncology, today announced the early conclusion based on...
Source: prnewswire.com